
Capricor Therapeutics Faces Securities Litigation Over Drug Trial Disclosures
Investors who purchased Capricor Therapeutics stock between December 17, 2025, and July 29, 2026, are being courted by The Gross Law Firm to join a class-action lawsuit. The firm is currently seeking a lead plaintiff to represent shareholders following allegations of misleading statements regarding the company’s lead product candidate, Deramiocel.























